BioNTech revenue and financials
$96.86Change from previous close: −0.80%Absolute change: −$0.78
In the fiscal year ended December 2025, BioNTech reported revenue of €2.87B (+4.32% year over year). The net loss was €1.14B.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.32%
- 2025 vs 2024
- Net margin
- -39.6%
- 2024: -24.2%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 2,870 | 2,751 | 3,819 | 17,311 | 18,977 | 482 | 109 | 128 | 61.6 |
| Cost of revenue | 642 | 541 | 600 | 2,995 | 2,912 | 59.3 | 17.4 | 13.7 | 9.3 |
| Gross profit | 2,259 | 2,210 | 3,219 | 14,316 | 16,065 | — | 91.2 | 114 | 52.3 |
| Selling, general and administrative | 624 | 599 | 558 | 541 | 327 | — | — | — | — |
| Research and development | 2,105 | 2,254 | 1,783 | 1,537 | 949 | 645 | 227 | 143 | 85.5 |
| Operating income | -1,405 | -1,314 | 690 | 12,643 | 15,284 | -82.4 | -182 | -53.9 | -61.3 |
| EBIT | -1,267 | -1,286 | 972 | 11,918 | 14,847 | — | — | — | — |
| EBITDA | -1,124 | -1,175 | 1,110 | 11,983 | 14,893 | — | — | — | — |
| Interest expense | 69.8 | 27.4 | 23.9 | 18.9 | 305 | 65.0 | 2.0 | 0.0 | 26.0 |
| Pre-tax income | -1,051 | -678 | 1,186 | 12,954 | 15,046 | — | — | — | — |
| Income tax | 85.3 | -12.4 | 256 | 3,520 | 4,754 | -161 | -0.2 | 0.6 | 0.0 |
| Net income | -1,136 | -665 | 930 | 9,434 | 10,293 | 15.2 | -179 | -48.0 | -85.7 |
| Net income to common shareholders | -1,136 | -665 | 930 | 9,434 | 10,293 | — | — | — | — |
| Basic EPS | -4.70 | -2.77 | 3.87 | 38.78 | 42.18 | 0.06 | -0.85 | — | — |
| Diluted EPS | -4.70 | -2.77 | 3.83 | 37.77 | 39.63 | 0.06 | -0.85 | — | — |
| Average shares (basic) | 242 | 240 | 241 | 243 | 244 | — | — | — | — |
| Average shares (diluted) | 242 | 240 | 243 | 250 | 260 | — | — | — | — |